{
    "nctId": "NCT00785213",
    "title": "An Open-Label Drug-Drug Interaction Study to Investigate the Effects of Steady State Quinine on the Single-Dose Pharmacokinetics of Rosiglitazone Maleate in Healthy Volunteers",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Healthy adults 18-45 years of age"
                    },
                    {
                        "type": "variable",
                        "value": "Non-smoking"
                    },
                    {
                        "type": "variable",
                        "value": "Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)"
                    },
                    {
                        "type": "variable",
                        "value": "Body mass index (BMI) less than or equal to 32"
                    },
                    {
                        "type": "variable",
                        "value": "Medically healthy on the basis of medical history and physical examination"
                    },
                    {
                        "type": "variable",
                        "value": "Hemoglobin \\> or = to 11.5g/dL"
                    },
                    {
                        "type": "variable",
                        "value": "Completion of the screening process within 28 days prior to dosing"
                    },
                    {
                        "type": "variable",
                        "value": "Provision of voluntary written informed consent"
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 18 Years"
                    },
                    {
                        "type": "variable",
                        "value": "Must have maximum age of 45 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Recent participation (within 28 days) in other research studies"
                            },
                            {
                                "type": "variable",
                                "value": "Recent significant blood donation or plasma donation"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or lactating"
                            },
                            {
                                "type": "variable",
                                "value": "Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)"
                            },
                            {
                                "type": "variable",
                                "value": "Recent (2-year) history or evidence of alcoholism or drug abuse"
                            },
                            {
                                "type": "variable",
                                "value": "History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease"
                            },
                            {
                                "type": "variable",
                                "value": "Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study"
                            },
                            {
                                "type": "variable",
                                "value": "Drug allergies to quinine sulfate or rosiglitazone"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Body mass index (BMI) less than or equal to 32'), Symbol('Completion of the screening process within 28 days prior to dosing'), Symbol('Healthy adults 18-45 years of age'), Symbol('Hemoglobin \\\\> or = to 11.5g/dL'), Symbol('Medically healthy on the basis of medical history and physical examination'), Symbol('Must have maximum age of 45 Years'), Symbol('Must have minimum age of 18 Years'), Symbol('Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)'), Symbol('Non-smoking'), Symbol('Provision of voluntary written informed consent'), Not(Or(Symbol('Drug allergies to quinine sulfate or rosiglitazone'), Symbol('History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease'), Symbol('Pregnant or lactating'), Symbol('Recent (2-year) history or evidence of alcoholism or drug abuse'), Symbol('Recent participation (within 28 days) in other research studies'), Symbol('Recent significant blood donation or plasma donation'), Symbol('Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study'), Symbol('Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)'))))"
}